Novavax (NVAX) Other Operating Expenses (2011 - 2026)

Novavax's Other Operating Expenses history runs 10 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 117.46% year-over-year to $30.7 million in Q1 2026; TTM through Mar 2026 was $187.5 million, a 18.92% increase from a year earlier, with the FY2024 full-year figure at $51.9 million, changed N/A from the prior year.
• Other Operating Expenses improved to $30.7 million in Q1 2026 per NVAX's latest filing, from $22.9 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $434.6 million in Q3 2022 and bottomed at $14.1 million in Q1 2025.
• The 5-year median for Other Operating Expenses is $55.8 million (2023), against an average of $97.1 million.
• Biggest YoY gain for Other Operating Expenses was 124.19% in 2023; the steepest drop was 79.42% in 2023.
• Year by year, Other Operating Expenses stood at $181.8 million in 2022, then dropped by 14.74% to $155.0 million in 2023, then tumbled by 76.34% to $36.7 million in 2024, then slumped by 37.52% to $22.9 million in 2025, then surged by 33.97% to $30.7 million in 2026.
• Per Business Quant, the three latest NVAX Other Operating Expenses figures stand at $30.7 million (Q1 2026), $22.9 million (Q4 2025), and $118.5 million (Q3 2025).